{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:04:02Z","timestamp":1781024642817,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":89,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009528","name":"Children's Foundation of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009528","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gastha.2026.100953","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:33:54Z","timestamp":1775579634000},"page":"100953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Proactive Therapeutic Drug Monitoring on Infliximab Maintenance Therapy and Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Randomized Controlled Trial and Review of Literature"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9151-7846","authenticated-orcid":false,"given":"Kristen","family":"Cares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Stolinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"El-Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.gastha.2026.100953_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11894-018-0623-z","article-title":"Therapeutic drug monitoring in pediatric inflammatory bowel disease","volume":"20","author":"Carman","year":"2018","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"10.1016\/j.gastha.2026.100953_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/ibd\/izy203","article-title":"Proactively optimized infliximab monotherapy is as effective as combination therapy in IBD","volume":"25","author":"Lega","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.gastha.2026.100953_bib3","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/ibd\/izab285","article-title":"Dashboard-driven accelerated infliximab induction dosing increases infliximab durability and reduces immunogenicity","volume":"28","author":"Dubinsky","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"7 Suppl 4","key":"10.1016\/j.gastha.2026.100953_bib4","first-page":"1","article-title":"Therapeutic monitoring of anti-TNF levels and antibodies to predict response and achieve mucosal healing","volume":"10","author":"Rutgeerts","year":"2014","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"8","key":"10.1016\/j.gastha.2026.100953_bib5","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ibd\/izaa265","article-title":"Therapeutic drug monitoring of tumor necrosis factor antagonists in crohn disease: a theoretical construct to pharmacokinetics and guidelines to clinical practice","volume":"27","author":"Vande Casteele","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.gastha.2026.100953_bib6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jpn3.12074","article-title":"Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease","volume":"78","author":"Zitomersky","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.gastha.2026.100953_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MPG.0000000000002112","article-title":"Causes of treatment failure in children with inflammatory bowel disease treated with infliximab","volume":"68","author":"Naviglio","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.gastha.2026.100953_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.gastha.2023.11.004","article-title":"Body surfaced area based-dosing of infliximab is superior to standard weight-based dosing in children with very early onset inflammatory bowel disease","volume":"3","author":"Stallard","year":"2023","journal-title":"Gastro Hep Adv"},{"issue":"5","key":"10.1016\/j.gastha.2026.100953_bib9","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.cgh.2022.08.016","article-title":"Multicenter cohort study of Infliximab pharmacokinetics and therapy response in pediatric acute severe ulcerative colitis","volume":"21","author":"Whaley","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.gastha.2026.100953_bib10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/FTD.0000000000001095","article-title":"Challenges in therapeutic drug monitoring: optimizing biological treatments in patients with inflammatory bowel disease and other immune-mediated inflammatory diseases","volume":"45","author":"Papamichael","year":"2023","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.gastha.2026.100953_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057656","article-title":"Proactive infliximab optimization using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre open-label study (the OPTIMIZE trial)","volume":"12","author":"Papamichael","year":"2022","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.gastha.2026.100953_bib12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/j.gastro.2022.06.052","article-title":"Proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: a systematic review and meta-analysis","volume":"163","author":"Nguyen","year":"2022","journal-title":"Gastroenterology"},{"issue":"7 Suppl 4","key":"10.1016\/j.gastha.2026.100953_bib13","first-page":"1","article-title":"Prospective therapeutic drug monitoring and optimization of infliximab maintenance therapy in IBD","volume":"10","author":"Vaughn","year":"2014","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"4","key":"10.1016\/j.gastha.2026.100953_bib14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MPG.0000000000003389","article-title":"Advantages of proactive therapeutic drug monitoring in a prospective cohort of children with inflammatory bowel disease treated with anti-TNF necrosis factor","volume":"74","author":"Gasparetto","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"11","key":"10.1016\/j.gastha.2026.100953_bib15","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1097\/MIB.0000000000000156","article-title":"Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study","volume":"20","author":"Vaughn","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.gastha.2026.100953_bib16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/archdischild-2018-315100","article-title":"Utility of proactive infliximab levels in paediatric Crohn's disease","volume":"104","author":"Burgess","year":"2019","journal-title":"Arch Dis Child"},{"issue":"12","key":"10.1016\/j.gastha.2026.100953_bib17","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/apt.17313","article-title":"Meta-analysis: the efficacy of therapeutic drug monitoring of anti-TNF-Therapy in inflammatory bowel disease","volume":"57","author":"Sethi","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.gastha.2026.100953_bib18","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/MIB.0000000000000137","article-title":"Early infliximab trough levels are associated with persistent remission in pediatirc patients with inflammatory bowel disease","volume":"20","author":"Singh","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastha.2026.100953_bib19","article-title":"The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update","volume":"7","author":"Van Rheenen","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"7","key":"10.1016\/j.gastha.2026.100953_bib20","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of Infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.gastha.2026.100953_bib21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1053\/j.gastro.2019.06.003","article-title":"Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn's disease compared with reactive monitoring","volume":"157","author":"Assa","year":"2019","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gastha.2026.100953_bib22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQoL Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"issue":"3","key":"10.1016\/j.gastha.2026.100953_bib23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.dld.2023.06.028","article-title":"Efficacy and safety of proactive drug monitoring in inflammatory bowel disease treated with anti-TNF agents: a systematic review and meta-analysis","volume":"56","author":"Marcos","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.gastha.2026.100953_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-077193","article-title":"Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA","volume":"14","author":"Minar","year":"2024","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.gastha.2026.100953_bib25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/apt.16733","article-title":"Antibodies-to-Infliximab clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease","volume":"55","author":"Colman","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.gastha.2026.100953_bib26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/MPG.0000000000002631","article-title":"Pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in pediatric inflammatory bowel disease: a systematic review and revised dosing considerations","volume":"70","author":"Winter","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.gastha.2026.100953_bib27","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cpt.2148","article-title":"Real-world infliximab pharmacokinetic study informs an electronic health record-embedded dashboard to guide precision dosing in children with Crohn's disease","volume":"109","author":"Xiong","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.gastha.2026.100953_bib28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/ibd\/izaa102","article-title":"Effect of a practice-wide anti-TNF proactive therapeutic monitoring program on outcomes in pediatric patients with inflammatory bowel disease","volume":"27","author":"Lyles","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.gastha.2026.100953_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/ibd\/izz131","article-title":"Proactive Infliximab drug monitoring is superior to conventional management in inflammatory bowel disease","volume":"26","author":"Fernandes","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.gastha.2026.100953_bib30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/MPG.0000000000002704","article-title":"Optimizing antitumor necrosis factor treatment in pediatric inflammatory bowel disease with therapeutic drug monitoring","volume":"71","author":"Pinto Pais","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10.1016\/j.gastha.2026.100953_bib31","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPG.0000000000001029","article-title":"Practical use of Infliximab concentration monitoring in pediatric Crohn's disease","volume":"62","author":"Minar","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"11","key":"10.1016\/j.gastha.2026.100953_bib32","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjy111","article-title":"Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease","volume":"12","author":"van Hoeve","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastha.2026.100953_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cgh.2025.04.025","article-title":"Proactive drug monitoring versus clinically based dosing for endoscopic healing in pediatric Crohn's disease receiving infliximab","volume":"24","author":"Kang","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.100953_bib34","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/jpn3.70158","article-title":"North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the therapeutic drug monitoring in pediatic inflammatory bowel disease","volume":"81","author":"Felipez","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"8","key":"10.1016\/j.gastha.2026.100953_bib35","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/ibd\/izac237","article-title":"Model-informed precision dosing for biologics is now available at the bedside for patients with inflammatory bowel disease","volume":"29","author":"Colman","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.gastha.2026.100953_bib38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/00365521.2020.1856405","article-title":"Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial","volume":"56","author":"Strik","year":"2021","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1016\/j.gastha.2026.100953_bib39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/ibd\/izz143","article-title":"Improved population pharmacokinetic model for predicting optimized infliximab exposure in pediatric inflammatory bowel disease","volume":"26","author":"Bauman","year":"2020","journal-title":"Inflamm Bowel Dis"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326000749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326000749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:50:58Z","timestamp":1781023858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572326000749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2772572326000749"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2026.100953","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Proactive Therapeutic Drug Monitoring on Infliximab Maintenance Therapy and Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Randomized Controlled Trial and Review of Literature","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2026.100953","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}],"article-number":"100953"}}